Dr. Ramjeesingh holds an MD and PhD from the University of Toronto and completed residency training in internal medicine and medical oncology through Queen’s University. He then undertook a two-year clinical trial methodology and translational research fellowship with the NCIC Clinical Trials Group at Queen’s. His work focused on the appropriate timing of administration of adjuvant chemotherapy to patients with breast cancer.

Dr. Ramjeesingh focuses his clinical practice on treatment of breast cancer, gastrointestinal cancers, including hepatocellular carcinoma, pancreatic and cholangiocarcinomas, and melanoma. His primary research interests include translational and health services research, and oncology education of residents and medical students.

Ramjeesingh, R., Orr, C., Bricks, CS., Hopman, WM., and Hammad, N. (2016). A retrospective study on the role of diabetes and metformin in colorectal cancer disease survival. Current Oncology, 23(2): e116-122. Ramjeesingh, R., Meyer, RM., Brouwers, M., Booth, CM. (2013). Alignment of practice guidelines with targeted therapy drug funding policies in Ontario. Current Oncology, 20(1): e21-33. Ramjeesingh, R., Quan, ML., Gardner, S., Holloway, CM. (2009). Prediction of involvement of sentinel and non-sentinel lymph nodes in a Canadian population with breast cancer. Canadian Journal of Surgery, 52: 23-30. Ramjeesingh, RA., Leung, R., and Siu, C-H. (2003). Interleukin-8 secreted by endothelial cells induces chemotaxis of melanoma cells through the chemokine receptor CXCR1. FASEB, 17: 1292-1294. Voura, EB., Ramjeesingh, RA., Montgomery, AM., Siu, C-H. (2001). Involvement of integrin a(v)b(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. Mol. Bio. Cell, 12: 2699-2710.